Skip to main
  1. Stocks
  2. Geron
  3. Forecast
GERN

Geron (GERN) Stock Forecast & Price Target

Geron (GERN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Geron is supported by a commercial story that is now anchored by RYTELO’s approved LR-MDS franchise, where management reported $57.5M of revenue in 2Q:26, 11% sequential growth, about 1,575 ordering accounts, and gross-to-net in the low 20% range. The 2026 IMpactMF discontinuation removes a potential myelofibrosis upside stream, but the lack of new safety signals and the belief that the control arm improved over time suggest the decision does not undermine imetelstat’s biology or RYTELO’s physician adoption. With NCCN preferred status in 1L and 2L settings, ongoing community expansion, $221M in estimated YE:26 net cash, and a high-probability MDS outlook, the fundamentals still justify a constructive view.

Bears say

Geron is facing a weaker fundamental outlook because the Phase 3 IMpactMF trial in JAK inhibitor-relapsed/refractory myelofibrosis was discontinued after the independent Data Monitoring Committee said it was unlikely to meet its primary overall survival endpoint, removing a major growth opportunity from the model. The setback matters because the myelofibrosis program had been a key source of upside beyond the approved RYTELO franchise, and the company’s own analysis now drops MF credit despite no new safety signals and an unchanged imetelstat safety profile. Although the smaller Phase 2 MYF2001 study showed encouraging median overall survival of 29.9 months versus about 12 months in a matched real-world cohort, the limited sample size and reliance on external comparison data make that evidence insufficient to offset the late-stage failure.

Geron (GERN) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geron and is not a guaranteed prediction by Public.com or investment advice.

Geron (GERN) Analyst Forecast & Price Prediction

Get the latest Geron (GERN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Geron (GERN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geron (GERN) Forecast

Analysts have given Geron (GERN) a Buy based on their latest research and market trends.

According to 2 analysts, Geron (GERN) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geron (GERN)


Geron (GERN) Analyst Forecast & Price Prediction

Get the latest Geron (GERN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Geron (GERN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover GERN stock data and trends